NovaBridge Biosciences (NBP) Invested Capital (2017 - 2025)

NovaBridge Biosciences (NBP) has 9 years of Invested Capital data on file, last reported at $230.9 million in Q4 2025.

• Quarterly Invested Capital rose 14.8% year-over-year to $230.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $230.9 million (up 14.8% YoY) and the FY2025 annual result came in at $230.9 million, up 14.8% from the prior year.
• Invested Capital retreated to $230.9 million in Q4 2025 per NBP's latest filing, from $258.9 million in the prior quarter.
• Across five years, Invested Capital topped out at $845.6 million in Q2 2021 and bottomed at $196.7 million in Q2 2025.
• The 5-year median for Invested Capital is $242.8 million (2023), against an average of $362.8 million.
• The widest annual swing landed in 2022, when Invested Capital slumped 42.26%; it then advanced 18.83% in 2025.
• Tracing NBP's Invested Capital over 5 years: stood at $713.2 million in 2021, then tumbled by 42.26% to $411.8 million in 2022, then slumped by 41.04% to $242.8 million in 2023, then slipped by 17.15% to $201.2 million in 2024, then rose by 14.8% to $230.9 million in 2025.
• Per Business Quant, the three latest NBP Invested Capital figures stand at $230.9 million (Q4 2025), $258.9 million (Q3 2025), and $196.7 million (Q2 2025).

Peer Comparison